Statement: cohort 2 patients in the primary clinical trial are also given ipatasertib.
Primary_evidence: INTERVENTION 1:    Ipatasertib + Paclitaxel   Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses). INTERVENTION 2:    Placebo + Paclitaxel   Participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).